Biotech and Pharmaceuticals
Trump policies, China’s biotech boom are ending Europe’s pharma powerhouse era
Boxes of medication are seen on the shelves of the Keencare pharmacy, a member of the Green Light Group, on September 19, 2024 in London, England. Leon Neal | Getty Images News | Getty Images Once the go-to location for global drugmakers, Europe is now being squeezed by President Donald Trump’s aggressive trade and drug-pricing […]
Read More
Novo Nordisk’s explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t enough.” Zuckerman, a 32-year-old data analyst based in Washington, D.C., said she lost 90 pounds in college and spent years cycling through nutritionists, therapy and strict routines — only to find herself at her heaviest […]
Read More
Trump administration finalizes better-than-feared Medicare Advantage payment rate in boost to health insurers
Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz speaks during an event sponsored by the Action for Progress Coalition, at the National Press Club in Washington, D.C., U.S., Feb. 2, 2026. Al Drago | Reuters The Trump administration on Monday finalized a 2027 payment rate increase to privately run Medicare plans that […]
Read More
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
Piotr Swiat | Lightrocket | Getty Images Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused drugmaker’s expansion into metabolic disorders. The deal gives Neurocrine access to Vykat XR, the first drug approved in the U.S. to treat hyperphagia associated with Prader-Willi syndrome, […]
Read More
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC has learned. Patented medications and their active ingredients would be hit with a 100% tariff, according to a draft of the document obtained by […]
Read More
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images The Wegovy pill showed more pronounced weight loss and less cumbersome side effects than Eli Lilly‘s rival pill that was approved this week, Novo Nordisk said Thursday. Oral Wegovy demonstrated “significantly greater mean weight loss” than orforglipron, which Lilly will sell under the […]
Read More
How Ireland became dependent on big pharma — and the risks ahead
In just 50 years, Ireland has become the world’s third largest exporter of pharmaceuticals, with medicines now making up about 20% of Ireland’s GDP. So how did Ireland become so tied to the pharma industry — and is that reliance at risk amid tariffs, patent cliffs and geopolitical tension? Ireland manufactures some of the world’s […]
Read More
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients see lower, “predictable” monthly prices. Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two […]
Read More
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, Nov. 21, 2025. Mike Blake | Reuters BEIJING — U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market. The agreement will give Insilico […]
Read More
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
A sign of Swiss pharmaceutical giant Novartis is seen on the top of a building at Novartis Campus in Basel, northern Switzerland, on Sept. 9, 2025. Fabrice Coffrini | AFP | Getty Images Novartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may prove […]
Read More